Laurel, MD (PRWEB) September 23, 2009
Prophetic Consulting LLC, a leading provider of independent investment research on small and micro-cap biotechnology and pharmaceutical companies, today updated its research based tool, the FDA & BIOTECH Events Calendar with coverage on Allos Therapeutics, Inc..
Allos, Therapeutics is expecting a decision from the FDA on September 24th regarding its NDA for FOTOLYN (Pralatrexate) injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a form of cancer that develops from cells in the body known as T-cells. Pralatrexate is the company's lead drug candidate, making this decision a highly important milestone, if achieved.
Need details about this highly important milestone event? Prophetic Consulting, http://www.profeticconsult.com has provided free investor research on this and other upcoming small and micro cap biotech events.
To learn more: visit http://www.profeticconsult.com/fdabiotechcalendar.htm and click on September 2009 FDA & BIOTECH Events.
ABOUT PROPHETIC CONSULTING LLC.
Prophetic Consulting is the center of Information for the Biotech investor. Investor awareness plays an important role in how investors make decisions in the market place which is why Prophetic Consulting provides you with free independent investment research on small and micro cap biotech stocks and provides highly significant market sensitive news headlines in the biotech industry. Prophetic Consulting is devoted to creating an investment community of biotech investors and providing them with necessary tools and means to make important investment decisions. Our most precious research tool is our free FDA & BIOTECH Events Calendar which provides its users with important information on upcoming milestone events that could greatly impact a biotech company's stock price. To view our free calendar and take advantage of our other services go to http://www.profeticconsult.com
About Allos Therapeutics, Inc
Allos Therapeutics is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.